Targeted gene therapies NeuBase focuses on ultra precision genetic medicines for rare monogenic diseases and difficult cancers, presenting opportunities to partner on specialized delivery, validation, and regulatory pathways for niche indications.

Stealth Editors potential Recent coverage highlights Stealth Editors for in vivo gene editing with reduced immune response, signaling a potential collaboration avenue with pharma and biotech companies seeking improved safety and efficacy in genetic therapies.

Early-stage finance With a reported funding of around 14M and recent modest financing rounds, there may be room for strategic partnerships, co-development deals, or late-stage equity investments to accelerate clinical programs.

Leadership moves Key executive appointments and governance updates (CFO and President roles) indicate a maturing company ready to scale partnerships, financial management, and program commercialization strategies.

Collaborations and trials Past collaborations with Inserm on NT-0231 and active preclinical programs provide footholds for alliance discussions around joint development, access to model systems, and cross-institution study opportunities.